{"protocolSection":{"identificationModule":{"nctId":"NCT02527200","orgStudyIdInfo":{"id":"NN8022-4179"},"secondaryIdInfos":[{"id":"2014-004415-37","type":"EUDRACT_NUMBER"},{"id":"U1111-1162-7884","type":"OTHER","domain":"WHO"},{"id":"NL54145.078.15","type":"OTHER","domain":"CCMO"},{"id":"2014","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2014"}],"organization":{"fullName":"Novo Nordisk A/S","class":"INDUSTRY"},"briefTitle":"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome","officialTitle":"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome."},"statusModule":{"statusVerifiedDate":"2023-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-11-09","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-11-04","type":"ACTUAL"},"completionDateStruct":{"date":"2020-11-19","type":"ACTUAL"},"studyFirstSubmitDate":"2015-08-17","studyFirstSubmitQcDate":"2015-08-17","studyFirstPostDateStruct":{"date":"2015-08-18","type":"ESTIMATED"},"resultsFirstSubmitDate":"2021-10-27","resultsFirstSubmitQcDate":"2022-02-02","resultsFirstPostDateStruct":{"date":"2022-02-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-05","lastUpdatePostDateStruct":{"date":"2023-07-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Novo Nordisk A/S","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome."},"conditionsModule":{"conditions":["Metabolism and Nutrition Disorder","Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":56,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Liraglutide","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"type":"DRUG","name":"liraglutide","description":"Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.","armGroupLabels":["Liraglutide"]},{"type":"DRUG","name":"placebo","description":"Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks","description":"Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\\[(y / M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.","timeFrame":"Week 0, Week 16"},{"measure":"Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks","description":"Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\\[(y / M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.","timeFrame":"Week 0, Week 52"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16","description":"Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.","timeFrame":"At week 16"},{"measure":"Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52","description":"Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.","timeFrame":"At week 52"},{"measure":"Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16","description":"Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.","timeFrame":"At week 16"},{"measure":"Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52","description":"Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.","timeFrame":"At week 52"},{"measure":"Percentage of Participants With no Increase in BMI SDS at Week 16","description":"Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.","timeFrame":"At week 16"},{"measure":"Percentage of Participants With no Increase in BMI SDS at Week 52","description":"Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.","timeFrame":"At week 52"},{"measure":"Change in BMI From Baseline at Week 16","description":"Change in body mass index (BMI) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in BMI From Baseline at Week 52","description":"Change in body mass index (BMI) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Body Weight (Kilogram (kg)) From Baseline at Week 16","description":"Change in body weight (kg) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Body Weight (kg) From Baseline at Week 52","description":"Change in body weight (kg) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Body Weight (Pounds (lb)) From Baseline at Week 16","description":"Change in body weight (lb) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Body Weight (lb) From Baseline at Week 52","description":"Change in body weight (lb) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Body Weight (Percentage [%]) From Baseline at Week 16","description":"Change in body weight (%) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Body Weight (%) From Baseline at Week 52","description":"Change in body weight (%) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Waist Circumference From Baseline at Week 16","description":"Change in waist circumference from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Waist Circumference From Baseline at Week 52","description":"Change in waist circumference from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Waist-to-hip Circumference Ratio From Baseline at Week 16","description":"Change in waist-to-hip circumference ratio from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Waist-to-hip Circumference Ratio From Baseline at Week 52","description":"Change in waist-to-hip circumference ratio from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16","description":"Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52","description":"Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.","timeFrame":"Week 0, week 52"},{"measure":"Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16","description":"Change in hsCRP from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52","description":"Change in hsCRP from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Total Cholesterol From Baseline at Week 16","description":"Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Total Cholesterol From Baseline at Week 52","description":"Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16","description":"Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52","description":"Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16","description":"Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52","description":"Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16","description":"Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52","description":"Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16","description":"Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52","description":"Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Triglycerides From Baseline at Week 16","description":"Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Triglycerides From Baseline at Week 52","description":"Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16","description":"Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52","description":"Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16","description":"Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52","description":"Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16","description":"Change in HbA1c from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in HbA1c From Baseline at Week 52","description":"Change in HbA1c from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16","description":"Change in FPG from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in FPG From Baseline at Week 52","description":"Change in FPG from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Fasting Insulin From Baseline at Week 16","description":"Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Fasting Insulin From Baseline at Week 52","description":"Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Change in Fasting C Peptide From Baseline at Week 16","description":"Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.","timeFrame":"Week 0, week 16"},{"measure":"Change in Fasting C Peptide From Baseline at Week 52","description":"Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.","timeFrame":"Week 0, week 52"},{"measure":"Number of Participants in Glycaemic Category at Week 16","description":"Number of participants in glycaemic categories, \"normoglycaemia, pre-diabetes and type 2 diabetes\" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \\<5.6 mmol/L (\\<100 mg/dL) and/or HbA1c \\<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.","timeFrame":"week 16"},{"measure":"Number of Participants in Glycaemic Category at Week 52","description":"Number of participants in glycaemic categories, \"normoglycaemia, pre-diabetes and type 2 diabetes\" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \\<5.6 mmol/L (\\<100 mg/dL) and/or HbA1c \\<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.","timeFrame":"Week 52"},{"measure":"Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16","description":"Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\\[mU/L\\]/(FPG\\[mmol/L\\]-3.5).","timeFrame":"Week 0, week 16"},{"measure":"Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52","description":"Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\\[mU/L\\]/(FPG\\[mmol/L\\]-3.5).","timeFrame":"Week 0, week 52"},{"measure":"Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16","description":"Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \\[mmol/L\\] x fasting insulin \\[mmol/L\\]/ 22.5.","timeFrame":"Week 0, week 16"},{"measure":"Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52","description":"Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \\[mmol/L\\] x fasting insulin \\[mmol/L\\]/ 22.5.","timeFrame":"Week 0, week 52"},{"measure":"Number of Treatment Emergent Adverse Events","description":"An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).","timeFrame":"From week 0 to week 54"},{"measure":"Number of Severe Treatment Emergent Episodes of Hypoglycaemia","description":"Hypoglycaemic episode (blood glucose less than or equal to (\\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).","timeFrame":"From week 0 to week 54"},{"measure":"Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia","description":"Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \\< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).","timeFrame":"From week 0 to week 54"},{"measure":"Number of Participants With Occurrence of Anti-liraglutide Antibodies","description":"Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.","timeFrame":"From week 0 to week 54"},{"measure":"Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16","description":"A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.","timeFrame":"Week 0, Week 16"},{"measure":"Number of Participants With Change in ECG From Baseline at Week 52","description":"A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.","timeFrame":"Week 0, Week 52"},{"measure":"Change in Pulse From Baseline at Week 16","description":"Change in pulse from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Pulse From Baseline at Week 52","description":"Change in pulse from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Haematology: Haemoglobin From Baseline at Week 16","description":"Change in haemoglobin from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Haematology: Haemoglobin From Baseline at Week 52","description":"Change in haemoglobin from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Haematology: Haematocrit From Baseline at Week 16","description":"Change in haematocrit from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Haematology: Haematocrit From Baseline at Week 52","description":"Change in haematocrit from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16","description":"Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52","description":"Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Haematology: Erythrocytes From Baseline at Week 16","description":"Change in erythrocytes from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Haematology: Erythrocytes From Baseline at Week 52","description":"Change in erythrocytes from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16","description":"Change in creatinine and bilirubin (total) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52","description":"Change in creatinine and bilirubin (total) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16","description":"Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52","description":"Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16","description":"Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52","description":"Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Biochemistry: Albumin From Baseline at Week 16","description":"Change in albumin from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Biochemistry: Albumin From Baseline at Week 52","description":"Change in albumin from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16","description":"Change in CEA serum from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52","description":"Change in CEA serum from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Calcitonin From Baseline at Week 16","description":"Change in calcitonin from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Calcitonin From Baseline at Week 52","description":"Change in calcitonin from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16","description":"Change in TSH and prolactin from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52","description":"Change in TSH and prolactin from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16","description":"Change in free T4 and ACTH from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52","description":"Change in free T4 and ACTH from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16","description":"Change in IGF-1 and cortisol from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52","description":"Change in IGF-1 and cortisol from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16","description":"Change in DHEAS from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52","description":"Change in DHEAS from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16","description":"Change in LH and FSH from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52","description":"Change in LH and FSH from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Estradiol (Females) From Baseline at Week 16","description":"Change in estradiol (only for females) from baseline to week 16 is presented.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Estradiol (Females) From Baseline at Week 52","description":"Change in estradiol (only for females) from baseline to week 52 is presented.","timeFrame":"Week 0, week 52"},{"measure":"Change in Hormone Level: Testosterone (Males) From Baseline at Week 16","description":"Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.","timeFrame":"Week 0, week 16"},{"measure":"Change in Hormone Level: Testosterone (Males) From Baseline at Week 52","description":"Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.","timeFrame":"Week 0, week 52"},{"measure":"Number of Participants With Change in Pubertal Status From Baseline at Week 16","description":"This outcome measure presents \"pubertal status results\" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents \"early pubertal development\" and stage 5 represents \"pubertal development equivalent to that of an adult\".","timeFrame":"Week 0, week 16"},{"measure":"Number of Participants With Change in Pubertal Status From Baseline at Week 52","description":"This outcome measure presents \"pubertal status results\" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents \"early pubertal development\" and stage 5 represents \"pubertal development equivalent to that of an adult\".","timeFrame":"Week 0, week 52"},{"measure":"Number of Participants With Change in Physical Examination From Baseline at Week 16","description":"This outcome measure presents number of participants with physical examination findings, \"normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)\" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.","timeFrame":"Week 0, week 16"},{"measure":"Number of Participants With Change in Physical Examination From Baseline at Week 52","description":"This outcome measure presents number of participants with physical examination findings, \"normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)\" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.","timeFrame":"Week 0, week 52"},{"measure":"Height Velocity at Week 16","description":"Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.","timeFrame":"Week 16"},{"measure":"Height Velocity at Week 52","description":"Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.","timeFrame":"week 52"},{"measure":"Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16","description":"C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \\[C-CASA\\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is \"yes\" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is \"yes\" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with \"suicidal ideation or suicidal behaviour on C-SSRS\" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.","timeFrame":"Week 0, week 16"},{"measure":"Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52","description":"C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \\[C-CASA\\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is \"yes\" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is \"yes\" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with \"suicidal ideation or suicidal behaviour on C-SSRS\" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.","timeFrame":"Week 0, week 52"},{"measure":"Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16","description":"Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.","timeFrame":"Week 0, week 16"},{"measure":"Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52","description":"Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.","timeFrame":"Week 0, week 52"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial\n* Confirmed diagnosis of PWS (Prader-Willi Syndrome) (by genetic testing)\n* Male or female, age at the time of signing informed consent: - Part A: above or equal to 12 years and less than 18 years\n* Tanner stage 2-5 pubertal development for part A, and Tanner stage 1 for part B\n* BMI (body mass index) corresponding to equal or above 30 kg/m\\^2 for adults by international cut-off points1 and equal or above the 95th percentile for age and sex (for diagnosis of obesity)\n* Stable body weight during the previous 90 days before screening ( below 10 kg self-reported weight change)\n* Testing has been performed to evaluate for adrenal insufficiency and documented in medical record\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus (T1DM)\n* Type 2 diabetes mellitus (T2DM)\n* Calcitonin equal or above 50 ng/L\n* No change in treatment plan with growth hormone (GH) from randomisation to the end of the open-label period patients on growth hormone to stay on, patients off GH to stay off during this period. Adjustments in doses of growth hormone will be permitted)\n* Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroids Carcinoma (MTC)\n* History of pancreatitis (acute or chronic)\n* Treatment with any medication prescribed for weight loss within 90 days before screening (e.g. orlistat, zonisamide, topiramate/phentermine, lorcaserin, phentermine, bupropion/naltrexone,liraglutide, metformin)\n* Untreated adrenal insufficiency\n* Suggestive history of, or significant risk of gastroparesis (e.g. marked abdominal bloating post meal, history of vomiting, severe constipation), as judged by the Investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Novo Nordisk Investigational Site","city":"Santa Monica","state":"California","zip":"90404","country":"United States","geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"Novo Nordisk Investigational Site","city":"Baltimore","state":"Maryland","zip":"21229","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Novo Nordisk Investigational Site","city":"Buffalo","state":"New York","zip":"14203","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"Novo Nordisk Investigational Site","city":"Mineola","state":"New York","zip":"11501","country":"United States","geoPoint":{"lat":40.74927,"lon":-73.64068}},{"facility":"Novo Nordisk Investigational Site","city":"Columbus","state":"Ohio","zip":"43235","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"Novo Nordisk Investigational Site","city":"Camperdown","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"Novo Nordisk Investigational Site","city":"Parkville","state":"Victoria","zip":"3052","country":"Australia","geoPoint":{"lat":-37.78333,"lon":144.95}},{"facility":"Novo Nordisk Investigational Site","city":"Calgary","state":"Alberta","zip":"T3B 6A8","country":"Canada","geoPoint":{"lat":51.05011,"lon":-114.08529}},{"facility":"Novo Nordisk Investigational Site","city":"Montreal","state":"Quebec","zip":"H4A 3J1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"Novo Nordisk Investigational Site","city":"Angers","zip":"49033","country":"France","geoPoint":{"lat":47.47156,"lon":-0.55202}},{"facility":"Novo Nordisk Investigational Site","city":"Bordeaux","zip":"33076","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Novo Nordisk Investigational Site","city":"Brest","zip":"29609","country":"France","geoPoint":{"lat":48.39029,"lon":-4.48628}},{"facility":"Novo Nordisk Investigational Site","city":"Bron","zip":"69677","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"Novo Nordisk Investigational Site","city":"Haguenau","zip":"67504","country":"France","geoPoint":{"lat":48.81557,"lon":7.79051}},{"facility":"Novo Nordisk Investigational Site","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Novo Nordisk Investigational Site","city":"Marseille Cédex 05","zip":"13385","country":"France"},{"facility":"Novo Nordisk Investigational Site","city":"Montpellier","zip":"34295","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Novo Nordisk Investigational Site","city":"Nice","zip":"06200","country":"France","geoPoint":{"lat":43.70313,"lon":7.26608}},{"facility":"Novo Nordisk Investigational Site","city":"Paris","zip":"75012","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Novo Nordisk Investigational Site","city":"Paris","zip":"75015","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Novo Nordisk Investigational Site","city":"Rouen","zip":"76031","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"Novo Nordisk Investigational Site","city":"Toulouse","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Novo Nordisk Investigational Site","city":"Fiumicino","zip":"00050","country":"Italy","geoPoint":{"lat":41.77093,"lon":12.23662}},{"facility":"Novo Nordisk Investigational Site","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Novo Nordisk Investigational Site","city":"Padova","zip":"35128","country":"Italy","geoPoint":{"lat":44.38225,"lon":11.14261}},{"facility":"Novo Nordisk Investigational Site","city":"Rotterdam","zip":"3015 CN","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Novo Nordisk Investigational Site","city":"Grafton","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.86029,"lon":174.76566}},{"facility":"Novo Nordisk Investigational Site","city":"Ankara","zip":"06010","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34093","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Istanbul","zip":"34890","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Novo Nordisk Investigational Site","city":"Samsun","zip":"55139","country":"Turkey (Türkiye)","geoPoint":{"lat":41.27976,"lon":36.3361}},{"facility":"Novo Nordisk Investigational Site","city":"Trabzon","zip":"61080","country":"Turkey (Türkiye)","geoPoint":{"lat":41.005,"lon":39.72694}}]},"referencesModule":{"references":[{"pmid":"36181471","type":"RESULT","citation":"Diene G, Angulo M, Hale PM, Jepsen CH, Hofman PL, Hokken-Koelega A, Ramesh C, Turan S, Tauber M. Liraglutide for Weight Management in Children and Adolescents With Prader-Willi Syndrome and Obesity. J Clin Endocrinol Metab. 2022 Dec 17;108(1):4-12. doi: 10.1210/clinem/dgac549."}],"seeAlsoLinks":[{"label":"Clinical Trials at Novo Nordisk","url":"http://novonordisk-trials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"According to Novo Nordisk disclosure commitment on novonordisk-trials.com","url":"http://novonordisk-trials.com"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Trial has part A \\& B, participants entered sequentially into part A \\& B, and were randomised 2:1 (liraglutide/placebo). Part A conducted in adolescents (≥12-\\<18 years \\[yrs\\], Tanner stage 2-5) with Prader-Willi Syndrome (PWS) and obesity; Part B in children (≥6-˂12 yrs, Tanner stage below 2 with PWS and obesity. On part A 16-week double-blind period completion, data monitoring committee reviewed PK data to un-blind part A safety data then recommended randomisation (liraglutide/placebo) in part B.","recruitmentDetails":"The trial was conducted at 20 sites in 8 countries as follows: Australia (2), Canada (1), France (7), Italy (2), Netherlands (1), New Zealand (1), Turkey (3), and the United States (3).","groups":[{"id":"FG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"FG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"FG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"FG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"Safety Analysis Set (SAS)","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"Full Analysis Set (FAS)","achievements":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"17"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"9"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"7"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Unclassified","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Full analysis set (FAS) which included all randomised participants who received at least one dose of trial product and had any post-randomisation data.","groups":[{"id":"BG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"BG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"BG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"BG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"55"}]}],"measures":[{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"6 - <12 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"24"}]}]},{"title":"12 - <18 years","categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"31"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"28"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"27"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"5"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"47"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"34"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"17"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks","description":"Change in BMI SDS from baseline to week 16 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\\[(y / M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.","populationDescription":"Full analysis set (FAS) which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed\" = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"SDS score","timeFrame":"Week 0, Week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.21"},{"groupId":"OG001","value":"-0.18","spread":"0.23"},{"groupId":"OG002","value":"-0.50","spread":"0.65"},{"groupId":"OG003","value":"-0.48","spread":"0.39"},{"groupId":"OG004","value":"-0.33","spread":"0.49"},{"groupId":"OG005","value":"-0.29","spread":"0.32"}]}]}]},{"type":"PRIMARY","title":"Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 52 Weeks","description":"Change in BMI SDS from baseline to week 52 is presented. BMI SDS also called Z-scores, was calculated using the following formula: Z=\\[(y / M)\\^L - 1\\] / S\\*L; where L, M and S are median (M), Box-cox power (L) and variation coefficient (S) of children/adolescents', y= individual BMI. BMI provided for each sex and age. For each participant, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. Possible values range from -3 to +3, a negative score being beneficial.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"SDS score","timeFrame":"Week 0, Week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.37"},{"groupId":"OG001","value":"-0.13","spread":"0.25"},{"groupId":"OG002","value":"-0.79","spread":"1.21"},{"groupId":"OG003","value":"-0.71","spread":"0.68"},{"groupId":"OG004","value":"-0.50","spread":"0.88"},{"groupId":"OG005","value":"-0.36","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 16","description":"Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 16.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"27.8"},{"groupId":"OG001","value":"8.3"},{"groupId":"OG002","value":"37.5"},{"groupId":"OG003","value":"57.1"},{"groupId":"OG004","value":"32.4"},{"groupId":"OG005","value":"26.3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"72.2"},{"groupId":"OG001","value":"91.7"},{"groupId":"OG002","value":"62.5"},{"groupId":"OG003","value":"42.9"},{"groupId":"OG004","value":"67.6"},{"groupId":"OG005","value":"73.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ≥ 5% Reduction in Baseline BMI at Week 52","description":"Percentage of participants achieving more than or equal to (≥) 5% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 5% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 5% reduction in their baseline (week 0) BMI at week 52.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"29.4"},{"groupId":"OG001","value":"18.2"},{"groupId":"OG002","value":"35.7"},{"groupId":"OG003","value":"42.9"},{"groupId":"OG004","value":"32.3"},{"groupId":"OG005","value":"27.8"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"70.6"},{"groupId":"OG001","value":"81.8"},{"groupId":"OG002","value":"64.3"},{"groupId":"OG003","value":"57.1"},{"groupId":"OG004","value":"67.7"},{"groupId":"OG005","value":"72.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 16","description":"Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 16 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 16 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 16.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6.3"},{"groupId":"OG003","value":"14.3"},{"groupId":"OG004","value":"2.9"},{"groupId":"OG005","value":"5.3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"93.8"},{"groupId":"OG003","value":"85.7"},{"groupId":"OG004","value":"97.1"},{"groupId":"OG005","value":"94.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ≥ 10% Reduction in Baseline BMI at Week 52","description":"Percentage of participants achieving more than or equal to (≥) 10% reduction in their baseline (week 0) BMI at week 52 is presented. In below table, 'Yes' infers percentage of participants who achieved ≥ 10% reduction in their baseline (week 0) BMI at week 52 and 'No' infers percentage of participants who did not achieve ≥ 10% reduction in their baseline (week 0) BMI at week 52.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14.3"},{"groupId":"OG003","value":"28.6"},{"groupId":"OG004","value":"12.9"},{"groupId":"OG005","value":"11.1"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"88.2"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"85.7"},{"groupId":"OG003","value":"71.4"},{"groupId":"OG004","value":"87.1"},{"groupId":"OG005","value":"88.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With no Increase in BMI SDS at Week 16","description":"Percentage of participants with no increase in BMI SDS at week 16 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 16 and 'No' infers percentage of participants with increase in BMI SDS at week 16.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"66.7"},{"groupId":"OG001","value":"75.0"},{"groupId":"OG002","value":"87.5"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"76.5"},{"groupId":"OG005","value":"84.2"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"25.0"},{"groupId":"OG002","value":"12.5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"23.5"},{"groupId":"OG005","value":"15.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With no Increase in BMI SDS at Week 52","description":"Percentage of participants with no increase in BMI SDS at week 52 is presented. In below table, 'Yes' infers percentage of participants with no increase in BMI SDS at week 52 and 'No' infers percentage of participants with increase in BMI SDS at week 52.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"At week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"70.6"},{"groupId":"OG001","value":"72.7"},{"groupId":"OG002","value":"78.6"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"73.3"},{"groupId":"OG005","value":"81.3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"29.4"},{"groupId":"OG001","value":"27.3"},{"groupId":"OG002","value":"21.4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"26.7"},{"groupId":"OG005","value":"18.8"}]}]}]},{"type":"SECONDARY","title":"Change in BMI From Baseline at Week 16","description":"Change in body mass index (BMI) from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilogram per meter square (kg/m^2)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.4"},{"groupId":"OG001","value":"-0.8","spread":"1.6"},{"groupId":"OG002","value":"-1.1","spread":"1.5"},{"groupId":"OG003","value":"-1.5","spread":"1.7"},{"groupId":"OG004","value":"-1.0","spread":"1.4"},{"groupId":"OG005","value":"-1.1","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Change in BMI From Baseline at Week 52","description":"Change in body mass index (BMI) from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kg/m^2","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"2.2"},{"groupId":"OG001","value":"-0.1","spread":"2.1"},{"groupId":"OG002","value":"-0.6","spread":"3.3"},{"groupId":"OG003","value":"-0.7","spread":"2.7"},{"groupId":"OG004","value":"-0.7","spread":"2.7"},{"groupId":"OG005","value":"-0.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Kilogram (kg)) From Baseline at Week 16","description":"Change in body weight (kg) from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"(kilogram (kg))","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.6"},{"groupId":"OG001","value":"-1.1","spread":"5.0"},{"groupId":"OG002","value":"-0.6","spread":"2.2"},{"groupId":"OG003","value":"-1.0","spread":"2.7"},{"groupId":"OG004","value":"-1.2","spread":"3.0"},{"groupId":"OG005","value":"-1.0","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline at Week 52","description":"Change in body weight (kg) from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. (kilogram (kg))","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"kilogram","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.3"},{"groupId":"OG001","value":"1.9","spread":"6.0"},{"groupId":"OG002","value":"3.0","spread":"6.6"},{"groupId":"OG003","value":"2.8","spread":"5.2"},{"groupId":"OG004","value":"1.1","spread":"6.5"},{"groupId":"OG005","value":"2.3","spread":"5.6"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Pounds (lb)) From Baseline at Week 16","description":"Change in body weight (lb) from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pounds (lb)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"7.8"},{"groupId":"OG001","value":"-2.4","spread":"11.0"},{"groupId":"OG002","value":"-1.4","spread":"4.8"},{"groupId":"OG003","value":"-2.1","spread":"5.9"},{"groupId":"OG004","value":"-2.6","spread":"6.6"},{"groupId":"OG005","value":"-2.3","spread":"9.2"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (lb) From Baseline at Week 52","description":"Change in body weight (lb) from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pounds","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"13.9"},{"groupId":"OG001","value":"4.3","spread":"13.2"},{"groupId":"OG002","value":"6.7","spread":"14.4"},{"groupId":"OG003","value":"6.2","spread":"11.5"},{"groupId":"OG004","value":"2.5","spread":"14.4"},{"groupId":"OG005","value":"5.0","spread":"12.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (Percentage [%]) From Baseline at Week 16","description":"Change in body weight (%) from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percent change in body weight","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"3.8"},{"groupId":"OG001","value":"-0.7","spread":"3.7"},{"groupId":"OG002","value":"-1.1","spread":"4.1"},{"groupId":"OG003","value":"-2.2","spread":"5.5"},{"groupId":"OG004","value":"-1.4","spread":"3.9"},{"groupId":"OG005","value":"-1.2","spread":"4.3"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (%) From Baseline at Week 52","description":"Change in body weight (%) from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percent change in body weight","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"6.5"},{"groupId":"OG001","value":"2.3","spread":"5.7"},{"groupId":"OG002","value":"6.3","spread":"12.1"},{"groupId":"OG003","value":"4.9","spread":"8.6"},{"groupId":"OG004","value":"2.6","spread":"9.9"},{"groupId":"OG005","value":"3.3","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference From Baseline at Week 16","description":"Change in waist circumference from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"centimeters (cm)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":"4.52"},{"groupId":"OG001","value":"-2.44","spread":"7.84"},{"groupId":"OG002","value":"-0.73","spread":"6.14"},{"groupId":"OG003","value":"-1.04","spread":"4.53"},{"groupId":"OG004","value":"-1.70","spread":"5.31"},{"groupId":"OG005","value":"-1.92","spread":"6.70"}]}]}]},{"type":"SECONDARY","title":"Change in Waist Circumference From Baseline at Week 52","description":"Change in waist circumference from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"centimeter","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.98","spread":"8.68"},{"groupId":"OG001","value":"-3.48","spread":"7.32"},{"groupId":"OG002","value":"0.45","spread":"8.05"},{"groupId":"OG003","value":"0.97","spread":"5.99"},{"groupId":"OG004","value":"-1.49","spread":"8.45"},{"groupId":"OG005","value":"-2.09","spread":"7.06"}]}]}]},{"type":"SECONDARY","title":"Change in Waist-to-hip Circumference Ratio From Baseline at Week 16","description":"Change in waist-to-hip circumference ratio from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Waist-to-hip circumference ratio","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.04"},{"groupId":"OG001","value":"-0.02","spread":"0.06"},{"groupId":"OG002","value":"0.00","spread":"0.06"},{"groupId":"OG003","value":"0.01","spread":"0.04"},{"groupId":"OG004","value":"-0.01","spread":"0.05"},{"groupId":"OG005","value":"-0.01","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Change in Waist-to-hip Circumference Ratio From Baseline at Week 52","description":"Change in waist-to-hip circumference ratio from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"waist-to-hip circumference ratio","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.06"},{"groupId":"OG001","value":"-0.04","spread":"0.06"},{"groupId":"OG002","value":"-0.02","spread":"0.05"},{"groupId":"OG003","value":"-0.01","spread":"0.07"},{"groupId":"OG004","value":"-0.02","spread":"0.06"},{"groupId":"OG005","value":"-0.03","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 16","description":"Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 16 is presented. The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Hyperphagia behaviour score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.01"},{"groupId":"OG001","value":"-1.7","spread":"4.14"},{"groupId":"OG002","value":"-1.2","spread":"3.83"},{"groupId":"OG003","value":"-2.6","spread":"2.07"},{"groupId":"OG004","value":"-1.0","spread":"2.97"},{"groupId":"OG005","value":"-2.0","spread":"3.48"}]}]},{"title":"Hyperphagia drive score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.80"},{"groupId":"OG001","value":"-0.9","spread":"2.61"},{"groupId":"OG002","value":"-1.8","spread":"2.97"},{"groupId":"OG003","value":"-2.0","spread":"2.89"},{"groupId":"OG004","value":"-1.3","spread":"2.87"},{"groupId":"OG005","value":"-1.3","spread":"2.69"}]}]},{"title":"Hyperphagia severity score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.54"},{"groupId":"OG001","value":"-0.3","spread":"2.46"},{"groupId":"OG002","value":"-0.1","spread":"1.65"},{"groupId":"OG003","value":"0.1","spread":"1.46"},{"groupId":"OG004","value":"-0.4","spread":"1.59"},{"groupId":"OG005","value":"-0.2","spread":"2.12"}]}]},{"title":"Hyperphagia total score","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"5.55"},{"groupId":"OG001","value":"-2.9","spread":"5.79"},{"groupId":"OG002","value":"-3.1","spread":"7.28"},{"groupId":"OG003","value":"-4.4","spread":"5.65"},{"groupId":"OG004","value":"-2.7","spread":"6.34"},{"groupId":"OG005","value":"-3.5","spread":"5.63"}]}]}]},{"type":"SECONDARY","title":"Change in Hyperphagia Score: Total Score and Hyperphagic Behaviour, Drive and Severity Score From Baseline at Week 52","description":"Change in hyperphagia score (hyperphagia total score and hyperphagic behaviour, drive and severity score respectively), from baseline to week 52 is presented.The Hyperphagia Questionnaire (HQ)- Total Score. It contains 11 questions which are categorised into 3 subscales; Hyperphagic Behaviour, Hyperphagic Drive, and Hyperphagia Severity. The subscales are summed together to compute the Total Score. The Total Score ranges from 11-55, with higher scores indicating more hyperphagia and a worse outcome. The HQ-Behaviour Factor Score ranges from 5-25, with higher scores indicating more hyperphagic behaviours and a worse outcome. The HQ- Drive Factor Score ranges from 4-20, with higher scores indicating higher hyperphagic drive and a worse outcome. The HQ- Severity Factor Score ranges from 2-10, with higher scores indicating higher severity.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"16"}]}],"classes":[{"title":"Hyperphagia behaviour score","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"3.20"},{"groupId":"OG001","value":"-0.6","spread":"2.62"},{"groupId":"OG002","value":"-0.7","spread":"4.63"},{"groupId":"OG003","value":"-2.6","spread":"3.65"},{"groupId":"OG004","value":"-0.8","spread":"3.82"},{"groupId":"OG005","value":"-1.3","spread":"3.00"}]}]},{"title":"Hyperphagia drive score","categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"2.90"},{"groupId":"OG001","value":"-0.5","spread":"2.42"},{"groupId":"OG002","value":"-1.1","spread":"3.99"},{"groupId":"OG003","value":"-1.4","spread":"4.45"},{"groupId":"OG004","value":"-1.7","spread":"3.41"},{"groupId":"OG005","value":"-0.8","spread":"3.06"}]}]},{"title":"Hyperphagia severity score","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.81"},{"groupId":"OG001","value":"-0.9","spread":"2.51"},{"groupId":"OG002","value":"-0.4","spread":"2.73"},{"groupId":"OG003","value":"-1.4","spread":"1.82"},{"groupId":"OG004","value":"-0.9","spread":"2.27"},{"groupId":"OG005","value":"-1.1","spread":"2.26"}]}]},{"title":"Hyperphagia total score","categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"6.57"},{"groupId":"OG001","value":"-2.1","spread":"6.11"},{"groupId":"OG002","value":"-2.1","spread":"10.11"},{"groupId":"OG003","value":"-5.4","spread":"8.32"},{"groupId":"OG004","value":"-3.4","spread":"8.23"},{"groupId":"OG005","value":"-3.1","spread":"6.77"}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 16","description":"Change in hsCRP from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milligram per liter (mg/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.79","spread":"2.58"},{"groupId":"OG001","value":"-0.57","spread":"6.61"},{"groupId":"OG002","value":"-2.79","spread":"8.03"},{"groupId":"OG003","value":"1.87","spread":"2.12"},{"groupId":"OG004","value":"-0.61","spread":"5.57"},{"groupId":"OG005","value":"0.24","spread":"5.57"}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity C Reactive Protein (hsCRP) From Baseline at Week 52","description":"Change in hsCRP from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mg/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"2.55"},{"groupId":"OG001","value":"0.14","spread":"3.67"},{"groupId":"OG002","value":"-2.42","spread":"9.19"},{"groupId":"OG003","value":"-0.37","spread":"0.84"},{"groupId":"OG004","value":"-0.89","spread":"6.31"},{"groupId":"OG005","value":"-0.03","spread":"2.99"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol From Baseline at Week 16","description":"Change in Total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.10"},{"groupId":"OG001","value":"1.06","spread":"0.14"},{"groupId":"OG002","value":"1.02","spread":"0.11"},{"groupId":"OG003","value":"0.97","spread":"0.10"},{"groupId":"OG004","value":"1.00","spread":"0.10"},{"groupId":"OG005","value":"1.03","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol From Baseline at Week 52","description":"Change in total cholesterol (measured as millimoles per liter (mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of total cholesterol","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.18"},{"groupId":"OG001","value":"1.06","spread":"0.15"},{"groupId":"OG002","value":"1.01","spread":"0.12"},{"groupId":"OG003","value":"1.07","spread":"0.07"},{"groupId":"OG004","value":"1.01","spread":"0.15"},{"groupId":"OG005","value":"1.06","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 16","description":"Change in LDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of LDL-cholesterol","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.15"},{"groupId":"OG001","value":"1.13","spread":"0.19"},{"groupId":"OG002","value":"1.04","spread":"0.17"},{"groupId":"OG003","value":"0.96","spread":"0.14"},{"groupId":"OG004","value":"1.02","spread":"0.16"},{"groupId":"OG005","value":"1.07","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in Low Density Lipoprotein (LDL)-Cholesterol From Baseline at Week 52","description":"Change in LDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of LDL-cholesterol","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.22"},{"groupId":"OG001","value":"1.12","spread":"0.23"},{"groupId":"OG002","value":"0.99","spread":"0.19"},{"groupId":"OG003","value":"1.06","spread":"0.10"},{"groupId":"OG004","value":"1.01","spread":"0.20"},{"groupId":"OG005","value":"1.10","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 16","description":"Change in HDL-cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HDL-cholesterol","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":"0.14"},{"groupId":"OG001","value":"1.00","spread":"0.20"},{"groupId":"OG002","value":"1.01","spread":"0.14"},{"groupId":"OG003","value":"1.12","spread":"0.13"},{"groupId":"OG004","value":"0.98","spread":"0.14"},{"groupId":"OG005","value":"1.04","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change in High Density Lipoprotein (HDL)-Cholesterol From Baseline at Week 52","description":"Change in HDL-cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HDL-cholesterol","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.19"},{"groupId":"OG001","value":"1.02","spread":"0.17"},{"groupId":"OG002","value":"1.06","spread":"0.16"},{"groupId":"OG003","value":"1.08","spread":"0.12"},{"groupId":"OG004","value":"1.02","spread":"0.18"},{"groupId":"OG005","value":"1.04","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 16","description":"Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of non-HDL cholesterol","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.16"},{"groupId":"OG001","value":"1.09","spread":"0.15"},{"groupId":"OG002","value":"1.03","spread":"0.16"},{"groupId":"OG003","value":"0.93","spread":"0.12"},{"groupId":"OG004","value":"1.02","spread":"0.15"},{"groupId":"OG005","value":"1.04","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Non-high Density Lipoprotein (Non-HDL) Cholesterol From Baseline at Week 52","description":"Change in non-HDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of non-HDL cholesterol","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.22"},{"groupId":"OG001","value":"1.07","spread":"0.19"},{"groupId":"OG002","value":"1.00","spread":"0.16"},{"groupId":"OG003","value":"1.07","spread":"0.13"},{"groupId":"OG004","value":"1.01","spread":"0.19"},{"groupId":"OG005","value":"1.07","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 16","description":"Change in VLDL cholesterol (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of VLDL cholesterol","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.05","spread":"0.36"},{"groupId":"OG001","value":"0.98","spread":"0.27"},{"groupId":"OG002","value":"1.05","spread":"0.46"},{"groupId":"OG003","value":"0.80","spread":"0.17"},{"groupId":"OG004","value":"1.05","spread":"0.40"},{"groupId":"OG005","value":"0.93","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change in Very Low-density Lipoprotein (VLDL) Cholesterol From Baseline at Week 52","description":"Change in VLDL cholesterol (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of VLDL cholesterol","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.06","spread":"0.35"},{"groupId":"OG001","value":"0.95","spread":"0.36"},{"groupId":"OG002","value":"1.03","spread":"0.26"},{"groupId":"OG003","value":"1.13","spread":"0.31"},{"groupId":"OG004","value":"1.04","spread":"0.31"},{"groupId":"OG005","value":"1.01","spread":"0.34"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides From Baseline at Week 16","description":"Change in triglycerides (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.04","spread":"0.36"},{"groupId":"OG001","value":"0.99","spread":"0.26"},{"groupId":"OG002","value":"1.05","spread":"0.44"},{"groupId":"OG003","value":"0.80","spread":"0.18"},{"groupId":"OG004","value":"1.05","spread":"0.39"},{"groupId":"OG005","value":"0.93","spread":"0.25"}]}]}]},{"type":"SECONDARY","title":"Change in Triglycerides From Baseline at Week 52","description":"Change in triglycerides (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of triglycerides","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.07","spread":"0.36"},{"groupId":"OG001","value":"0.94","spread":"0.36"},{"groupId":"OG002","value":"1.04","spread":"0.29"},{"groupId":"OG003","value":"1.12","spread":"0.32"},{"groupId":"OG004","value":"1.06","spread":"0.32"},{"groupId":"OG005","value":"1.00","spread":"0.35"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 16","description":"Change in free fatty acids (measured as mmol/L) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of FFA","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"1.60"},{"groupId":"OG001","value":"1.31","spread":"0.61"},{"groupId":"OG002","value":"1.04","spread":"0.35"},{"groupId":"OG003","value":"0.99","spread":"0.30"},{"groupId":"OG004","value":"1.31","spread":"1.21"},{"groupId":"OG005","value":"1.21","spread":"0.55"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Lipid: Free Fatty Acids (FFA) From Baseline at Week 52","description":"Change in free fatty acids (measured as mmol/L) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of FFA","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"0.76"},{"groupId":"OG001","value":"1.45","spread":"0.49"},{"groupId":"OG002","value":"0.85","spread":"0.51"},{"groupId":"OG003","value":"1.05","spread":"0.25"},{"groupId":"OG004","value":"1.01","spread":"0.67"},{"groupId":"OG005","value":"1.32","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure From Baseline at Week 16","description":"Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"SBP: Change from week 0 to week 16","categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"15"},{"groupId":"OG001","value":"-2","spread":"13"},{"groupId":"OG002","value":"2","spread":"9"},{"groupId":"OG003","value":"2","spread":"6"},{"groupId":"OG004","value":"-1","spread":"13"},{"groupId":"OG005","value":"-1","spread":"11"}]}]},{"title":"DBP: Change from week 0 to week 16","categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"10"},{"groupId":"OG001","value":"0","spread":"7"},{"groupId":"OG002","value":"1","spread":"8"},{"groupId":"OG003","value":"-1","spread":"17"},{"groupId":"OG004","value":"0","spread":"9"},{"groupId":"OG005","value":"0","spread":"11"}]}]}]},{"type":"SECONDARY","title":"Change in Systolic and Diastolic Blood Pressure From Baseline at Week 52","description":"Change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Millimeters of mercury (mmHg)","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"classes":[{"title":"SBP: Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"-5","spread":"6"},{"groupId":"OG001","value":"4","spread":"12"},{"groupId":"OG002","value":"4","spread":"15"},{"groupId":"OG003","value":"7","spread":"8"},{"groupId":"OG004","value":"-1","spread":"11"},{"groupId":"OG005","value":"5","spread":"11"}]}]},{"title":"DBP: Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"9"},{"groupId":"OG001","value":"5","spread":"13"},{"groupId":"OG002","value":"4","spread":"13"},{"groupId":"OG003","value":"1","spread":"7"},{"groupId":"OG004","value":"0","spread":"11"},{"groupId":"OG005","value":"4","spread":"12"}]}]}]},{"type":"SECONDARY","title":"Change in Glycosylated Haemoglobin (HbA1c) From Baseline at Week 16","description":"Change in HbA1c from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage point of HbA1c","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.1"},{"groupId":"OG001","value":"0","spread":"0.3"},{"groupId":"OG002","value":"-0.2","spread":"0.3"},{"groupId":"OG003","value":"-0.2","spread":"0.3"},{"groupId":"OG004","value":"-0.2","spread":"0.2"},{"groupId":"OG005","value":"-0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c From Baseline at Week 52","description":"Change in HbA1c from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage point of HbA1c","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.2"},{"groupId":"OG001","value":"0.1","spread":"0.3"},{"groupId":"OG002","value":"-0.2","spread":"0.4"},{"groupId":"OG003","value":"-0.1","spread":"0.3"},{"groupId":"OG004","value":"-0.2","spread":"0.3"},{"groupId":"OG005","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose (FPG) From Baseline at Week 16","description":"Change in FPG from baseline to week 16 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.5"},{"groupId":"OG001","value":"0.1","spread":"0.5"},{"groupId":"OG002","value":"-0.1","spread":"0.5"},{"groupId":"OG003","value":"0.2","spread":"0.4"},{"groupId":"OG004","value":"-0.2","spread":"0.5"},{"groupId":"OG005","value":"0.1","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline at Week 52","description":"Change in FPG from baseline to week 52 is presented.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"14"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.7"},{"groupId":"OG001","value":"0.3","spread":"0.8"},{"groupId":"OG002","value":"0","spread":"0.4"},{"groupId":"OG003","value":"0","spread":"0.4"},{"groupId":"OG004","value":"0","spread":"0.6"},{"groupId":"OG005","value":"0.2","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Insulin From Baseline at Week 16","description":"Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of fasting insulin","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"1.91"},{"groupId":"OG001","value":"0.78","spread":"0.32"},{"groupId":"OG002","value":"1.43","spread":"1.17"},{"groupId":"OG003","value":"1.32","spread":"0.68"},{"groupId":"OG004","value":"1.52","spread":"1.62"},{"groupId":"OG005","value":"0.97","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Insulin From Baseline at Week 52","description":"Change in fasting insulin (measured as picomoles per litre (pmol/L)) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of fasting insulin","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"2.33"},{"groupId":"OG001","value":"0.79","spread":"0.37"},{"groupId":"OG002","value":"1.45","spread":"1.27"},{"groupId":"OG003","value":"1.22","spread":"0.44"},{"groupId":"OG004","value":"1.78","spread":"1.94"},{"groupId":"OG005","value":"0.96","spread":"0.44"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting C Peptide From Baseline at Week 16","description":"Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 16 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of fasting C peptide","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.56"},{"groupId":"OG001","value":"0.86","spread":"0.20"},{"groupId":"OG002","value":"1.11","spread":"0.50"},{"groupId":"OG003","value":"1.08","spread":"0.44"},{"groupId":"OG004","value":"1.13","spread":"0.53"},{"groupId":"OG005","value":"0.94","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Change in Fasting C Peptide From Baseline at Week 52","description":"Change in fasting C peptide (measured as nano moles per liter (nmol/L)) from baseline to week 52 is presented as ratio to baseline.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of fasting C peptide","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","spread":"0.92"},{"groupId":"OG001","value":"0.91","spread":"0.23"},{"groupId":"OG002","value":"1.15","spread":"0.45"},{"groupId":"OG003","value":"1.09","spread":"0.30"},{"groupId":"OG004","value":"1.26","spread":"0.75"},{"groupId":"OG005","value":"0.98","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Glycaemic Category at Week 16","description":"Number of participants in glycaemic categories, \"normoglycaemia, pre-diabetes and type 2 diabetes\" at Week 16 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \\<5.6 mmol/L (\\<100 mg/dL) and/or HbA1c \\<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Normoglycaemia","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"13"}]}]},{"title":"Pre-diabetes","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"}]}]},{"title":"Type 2 diabetes","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants in Glycaemic Category at Week 52","description":"Number of participants in glycaemic categories, \"normoglycaemia, pre-diabetes and type 2 diabetes\" at Week 52 are presented. These categories were set as per the following criteria: 1) Normoglycaemia: FPG \\<5.6 mmol/L (\\<100 mg/dL) and/or HbA1c \\<5.7%. 2) Pre-diabetes: FPG 5.6-6.9 mmol/L (both inclusive), FPG 100-125 mg/dL (both inclusive) or HbA1c 5.7-6.4% (both inclusive). 3) Type 2 diabetes: FPG ≥7.0 mmol/L (≥126 mg/dL) and/or HbA1c ≥6.5%.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"14"}]}],"classes":[{"title":"Normoglycaemia","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"6"}]}]},{"title":"Pre-diabetes","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"7"}]}]},{"title":"Type 2 diabetes","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 16","description":"Change in HOMA-B from baseline to week 16 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\\[mU/L\\]/(FPG\\[mmol/L\\]-3.5).","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HOMA-B","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"1.93"},{"groupId":"OG001","value":"0.70","spread":"0.31"},{"groupId":"OG002","value":"1.55","spread":"1.04"},{"groupId":"OG003","value":"1.07","spread":"0.51"},{"groupId":"OG004","value":"1.63","spread":"1.59"},{"groupId":"OG005","value":"0.82","spread":"0.41"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment of Beta-cell Function (HOMA-B) From Baseline at Week 52","description":"Change in HOMA-B from baseline to week 52 is presented as ratio to baseline. HOMA-B was calculated as: Beta-cell function (%) = 20·fasting insulin\\[mU/L\\]/(FPG\\[mmol/L\\]-3.5).","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HOMA-B","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":"1.85"},{"groupId":"OG001","value":"0.65","spread":"0.30"},{"groupId":"OG002","value":"1.50","spread":"1.50"},{"groupId":"OG003","value":"1.25","spread":"0.50"},{"groupId":"OG004","value":"1.91","spread":"1.71"},{"groupId":"OG005","value":"0.88","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 16","description":"Change in HOMA-IR from baseline to week 16 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \\[mmol/L\\] x fasting insulin \\[mmol/L\\]/ 22.5.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HOMA-IR","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":"1.92"},{"groupId":"OG001","value":"0.80","spread":"0.35"},{"groupId":"OG002","value":"1.43","spread":"1.26"},{"groupId":"OG003","value":"1.33","spread":"0.82"},{"groupId":"OG004","value":"1.51","spread":"1.65"},{"groupId":"OG005","value":"0.97","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Baseline at Week 52","description":"Change in HOMA-IR from baseline to week 52 is presented as ratio to baseline. HOMA-IR was calculated as: Insulin resistance (%) = fasting plasma glucose \\[mmol/L\\] x fasting insulin \\[mmol/L\\]/ 22.5.","populationDescription":"FAS which included all randomised participants who received at least one dose of trial product and had any post-randomisation data. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Ratio of HOMA-IR","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.26","spread":"3.13"},{"groupId":"OG001","value":"0.88","spread":"0.50"},{"groupId":"OG002","value":"1.45","spread":"1.23"},{"groupId":"OG003","value":"1.24","spread":"0.48"},{"groupId":"OG004","value":"1.90","spread":"2.46"},{"groupId":"OG005","value":"1.02","spread":"0.51"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Adverse Events","description":"An adverse event (AE) was any untoward medical occurrence in a clinical trial participant administered or using a medicinal product, whether or not considered related to the medicinal product or usage. All AEs reported here are TEAEs. TEAE is defined as an event that had onset date during the on-treatment period. The endpoint was evaluated based on the data from on-treatment period. On-treatment period included AEs are with an onset date on or after the first day of trial product administration and any of the following dates, whichever came first: a) 14 days after the last day on trial product, or b) Follow-up visit (week 54) for participants with trial product discontinuation, or c) Last study visit (participants withdrawn without follow-up visit (week 54)).","populationDescription":"Safety analysis set (SAS) which included all participants exposed to at least one dose of trial product. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Events","timeFrame":"From week 0 to week 54","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"159"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"293"},{"groupId":"OG005","value":"45"}]}]}]},{"type":"SECONDARY","title":"Number of Severe Treatment Emergent Episodes of Hypoglycaemia","description":"Hypoglycaemic episode (blood glucose less than or equal to (\\<=) 3.9 mmol/L (70 mg/dL) Or greater than (\\>) 3.9 mmol/L (70 mg/dL) occurring in conjunction with hypoglycaemic symptoms) is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Severe hypoglycaemia defined by American Diabetes Association (ADA) 2013 and International Society for Paediatric and Adolescent Diabetes (ISPAD) 2018: hypoglycaemic episode associated with severe cognitive impairment requiring external assistance for recovery. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"From week 0 to week 54","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Blood Glucose Confirmed Symptomatic Episodes of Hypoglycaemia","description":"Symptomatic blood glucose confirmed hypoglycaemia: An episode that is blood glucose confirmed by plasma glucose value \\< 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. Hypoglycaemic episode is defined as treatment emergent if the onset of the episode was on or after the first day of exposure to randomised treatment and no later than 14 days after the last day on randomised treatment. Endpoint was evaluated based on data from in-trial period which was defined as events with onset date on or after the first day of trial product administration and no later than the last study visit (week 54).","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Episodes","timeFrame":"From week 0 to week 54","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Occurrence of Anti-liraglutide Antibodies","description":"Number of participants with occurrence of anti-liraglutide antibodies is presented. In the below table, 'Yes' infers number of participants with occurrence of anti- liraglutide antibodies and 'No' infers number of participants without anti- liraglutide antibodies.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall number of participants analysed = Number of participants with available data. Combined data of Part A and B for liraglutide was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From week 0 to week 54","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG002","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"25"}]}],"classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"22"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Electrocardiogram (ECG) From Baseline at Week 16","description":"A 12-lead ECG was performed at baseline (week 0) and week 16 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and weeks 16 are presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, Week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Week 0: Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"18"}]}]},{"title":"Week 0: Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 0: Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 16: Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}]},{"title":"Week 16: Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 16: Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in ECG From Baseline at Week 52","description":"A 12-lead ECG was performed at baseline (week 0) and week 52 and categorised as normal, abnormal and not clinically significant (abnormal NCS) or abnormal and clinically significant (abnormal CS). Number of participants in each ECG category at week 0 and week 52 are presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, Week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"Week 0: Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"18"}]}]},{"title":"Week 0: Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 0: Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 52: Normal","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"13"}]}]},{"title":"Week 52: Abnormal, NCS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 52: Abnormal, CS","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse From Baseline at Week 16","description":"Change in pulse from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats/minute","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"12"},{"groupId":"OG001","value":"-2","spread":"5"},{"groupId":"OG002","value":"1","spread":"16"},{"groupId":"OG003","value":"-9","spread":"10"},{"groupId":"OG004","value":"2","spread":"14"},{"groupId":"OG005","value":"-4","spread":"8"}]}]}]},{"type":"SECONDARY","title":"Change in Pulse From Baseline at Week 52","description":"Change in pulse from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Beats/minute","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"13"},{"groupId":"OG001","value":"-8","spread":"10"},{"groupId":"OG002","value":"10","spread":"11"},{"groupId":"OG003","value":"-6","spread":"8"},{"groupId":"OG004","value":"5","spread":"13"},{"groupId":"OG005","value":"-7","spread":"10"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Haemoglobin From Baseline at Week 16","description":"Change in haemoglobin from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"millimoles per liter (mmol/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"0.43"},{"groupId":"OG001","value":"0.06","spread":"0.28"},{"groupId":"OG002","value":"-0.20","spread":"1.22"},{"groupId":"OG003","value":"-0.07","spread":"0.55"},{"groupId":"OG004","value":"-0.19","spread":"0.84"},{"groupId":"OG005","value":"0.01","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Haemoglobin From Baseline at Week 52","description":"Change in haemoglobin from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.14","spread":"0.79"},{"groupId":"OG001","value":"-0.01","spread":"0.31"},{"groupId":"OG002","value":"-0.02","spread":"0.61"},{"groupId":"OG003","value":"-0.02","spread":"0.20"},{"groupId":"OG004","value":"-0.09","spread":"0.72"},{"groupId":"OG005","value":"-0.01","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Haematocrit From Baseline at Week 16","description":"Change in haematocrit from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of haematocrit in blood","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"2.1"},{"groupId":"OG001","value":"-0.5","spread":"1.3"},{"groupId":"OG002","value":"0.4","spread":"2.6"},{"groupId":"OG003","value":"-0.6","spread":"3.3"},{"groupId":"OG004","value":"-0.9","spread":"2.6"},{"groupId":"OG005","value":"-0.5","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Haematocrit From Baseline at Week 52","description":"Change in haematocrit from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of haematocrit in blood","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"4.0"},{"groupId":"OG001","value":"0","spread":"1.7"},{"groupId":"OG002","value":"-0.2","spread":"2.7"},{"groupId":"OG003","value":"-0.8","spread":"2.6"},{"groupId":"OG004","value":"-0.9","spread":"3.5"},{"groupId":"OG005","value":"-0.3","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 16","description":"Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells per liter (10^9/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"title":"Thrombocytes: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":"35"},{"groupId":"OG001","value":"-21","spread":"26"},{"groupId":"OG002","value":"8","spread":"66"},{"groupId":"OG003","value":"19","spread":"18"},{"groupId":"OG004","value":"7","spread":"49"},{"groupId":"OG005","value":"-8","spread":"30"}]}]},{"title":"Leukocytes: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.5"},{"groupId":"OG001","value":"-0.3","spread":"1.6"},{"groupId":"OG002","value":"-0.8","spread":"2.3"},{"groupId":"OG003","value":"-1.1","spread":"1.7"},{"groupId":"OG004","value":"-0.4","spread":"1.9"},{"groupId":"OG005","value":"-0.6","spread":"1.6"}]}]},{"title":"Eosinophils: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.09"},{"groupId":"OG001","value":"0.04","spread":"0.07"},{"groupId":"OG002","value":"-0.14","spread":"0.27"},{"groupId":"OG003","value":"0.07","spread":"0.32"},{"groupId":"OG004","value":"-0.07","spread":"0.20"},{"groupId":"OG005","value":"0.05","spread":"0.19"}]}]},{"title":"Neutrophils: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"1.08"},{"groupId":"OG001","value":"-0.22","spread":"1.62"},{"groupId":"OG002","value":"-0.28","spread":"1.59"},{"groupId":"OG003","value":"-1.35","spread":"1.33"},{"groupId":"OG004","value":"-0.06","spread":"1.31"},{"groupId":"OG005","value":"-0.62","spread":"1.58"}]}]},{"title":"Basophils: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.02"},{"groupId":"OG001","value":"0","spread":"0.02"},{"groupId":"OG002","value":"-0.01","spread":"0.04"},{"groupId":"OG003","value":"-0.01","spread":"0.04"},{"groupId":"OG004","value":"-0.01","spread":"0.03"},{"groupId":"OG005","value":"0","spread":"0.03"}]}]},{"title":"Lymphocytes: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.66"},{"groupId":"OG001","value":"-0.09","spread":"0.97"},{"groupId":"OG002","value":"-0.36","spread":"0.89"},{"groupId":"OG003","value":"0.09","spread":"0.85"},{"groupId":"OG004","value":"-0.29","spread":"0.76"},{"groupId":"OG005","value":"-0.02","spread":"0.91"}]}]},{"title":"Monocytes: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.06","spread":"0.17"},{"groupId":"OG001","value":"-0.04","spread":"0.12"},{"groupId":"OG002","value":"-0.05","spread":"0.17"},{"groupId":"OG003","value":"0.05","spread":"0.20"},{"groupId":"OG004","value":"0.01","spread":"0.18"},{"groupId":"OG005","value":"-0.01","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Thrombocytes, Leukocytes, Eosinophils, Neutrophils, Basophils, Lymphocytes, Monocytes From Baseline at Week 52","description":"Change in thrombocytes, leukocytes, eosinophils, neutrophils, basophils, lymphocytes, monocytes from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^9 cells per liter (10^9/L)","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"classes":[{"title":"Thrombocytes: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":"44"},{"groupId":"OG001","value":"-7","spread":"39"},{"groupId":"OG002","value":"-2","spread":"37"},{"groupId":"OG003","value":"37","spread":"70"},{"groupId":"OG004","value":"10","spread":"42"},{"groupId":"OG005","value":"5","spread":"49"}]}]},{"title":"Leukocytes: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.1"},{"groupId":"OG001","value":"-0.6","spread":"1.7"},{"groupId":"OG002","value":"-0.7","spread":"2.8"},{"groupId":"OG003","value":"0.3","spread":"3.0"},{"groupId":"OG004","value":"-0.4","spread":"1.9"},{"groupId":"OG005","value":"-0.3","spread":"2.1"}]}]},{"title":"Eosinophils: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.11"},{"groupId":"OG001","value":"0.03","spread":"0.19"},{"groupId":"OG002","value":"-0.13","spread":"0.36"},{"groupId":"OG003","value":"-0.17","spread":"0.13"},{"groupId":"OG004","value":"-0.05","spread":"0.24"},{"groupId":"OG005","value":"-0.03","spread":"0.20"}]}]},{"title":"Neutrophils: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"1.17"},{"groupId":"OG001","value":"-0.76","spread":"1.40"},{"groupId":"OG002","value":"-0.03","spread":"2.03"},{"groupId":"OG003","value":"-0.07","spread":"2.55"},{"groupId":"OG004","value":"0.05","spread":"1.53"},{"groupId":"OG005","value":"-0.55","spread":"1.75"}]}]},{"title":"Basophils: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.03"},{"groupId":"OG001","value":"0","spread":"0.04"},{"groupId":"OG002","value":"-0.01","spread":"0.04"},{"groupId":"OG003","value":"0.02","spread":"0.04"},{"groupId":"OG004","value":"-0.01","spread":"0.04"},{"groupId":"OG005","value":"0.01","spread":"0.04"}]}]},{"title":"Lymphocytes: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"0.67"},{"groupId":"OG001","value":"0.19","spread":"0.70"},{"groupId":"OG002","value":"-0.47","spread":"0.59"},{"groupId":"OG003","value":"0.39","spread":"0.49"},{"groupId":"OG004","value":"-0.36","spread":"0.63"},{"groupId":"OG005","value":"0.25","spread":"0.63"}]}]},{"title":"Monocytes: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.19"},{"groupId":"OG001","value":"-0.06","spread":"0.22"},{"groupId":"OG002","value":"-0.05","spread":"0.19"},{"groupId":"OG003","value":"0.14","spread":"0.20"},{"groupId":"OG004","value":"-0.04","spread":"0.19"},{"groupId":"OG005","value":"0","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Erythrocytes From Baseline at Week 16","description":"Change in erythrocytes from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells per liter (10^12/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.2"},{"groupId":"OG001","value":"0","spread":"0.2"},{"groupId":"OG002","value":"0.1","spread":"0.3"},{"groupId":"OG003","value":"0","spread":"0.3"},{"groupId":"OG004","value":"-0.1","spread":"0.3"},{"groupId":"OG005","value":"0","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Haematology: Erythrocytes From Baseline at Week 52","description":"Change in erythrocytes from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"10^12 cells per liter (10^12/L)","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.4"},{"groupId":"OG001","value":"0","spread":"0.2"},{"groupId":"OG002","value":"-0.1","spread":"0.3"},{"groupId":"OG003","value":"0","spread":"0"},{"groupId":"OG004","value":"-0.1","spread":"0.4"},{"groupId":"OG005","value":"0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 16","description":"Change in creatinine and bilirubin (total) from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"micro mole per liter (umol/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"Creatinine: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"5"},{"groupId":"OG001","value":"0","spread":"6"},{"groupId":"OG002","value":"2","spread":"7"},{"groupId":"OG003","value":"0","spread":"6"},{"groupId":"OG004","value":"1","spread":"5"},{"groupId":"OG005","value":"0","spread":"6"}]}]},{"title":"Bilirubin (total): Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"2"},{"groupId":"OG001","value":"0","spread":"2"},{"groupId":"OG002","value":"0","spread":"2"},{"groupId":"OG003","value":"1","spread":"2"},{"groupId":"OG004","value":"0","spread":"2"},{"groupId":"OG005","value":"0","spread":"2"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Creatinine and Bilirubin (Total) From Baseline at Week 52","description":"Change in creatinine and bilirubin (total) from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Creatinine: Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"8"},{"groupId":"OG001","value":"-4","spread":"9"},{"groupId":"OG002","value":"3","spread":"6"},{"groupId":"OG003","value":"5","spread":"3"},{"groupId":"OG004","value":"3","spread":"7"},{"groupId":"OG005","value":"-1","spread":"9"}]}]},{"title":"Bilirubin (total): Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"2"},{"groupId":"OG001","value":"2","spread":"3"},{"groupId":"OG002","value":"0","spread":"1"},{"groupId":"OG003","value":"2","spread":"3"},{"groupId":"OG004","value":"0","spread":"2"},{"groupId":"OG005","value":"2","spread":"3"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 16","description":"Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units per liter (U/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"Creatinine kinase: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-3","spread":"37"},{"groupId":"OG001","value":"16","spread":"45"},{"groupId":"OG002","value":"3","spread":"23"},{"groupId":"OG003","value":"-5","spread":"5"},{"groupId":"OG004","value":"-1","spread":"32"},{"groupId":"OG005","value":"10","spread":"39"}]}]},{"title":"Amylase: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"13"},{"groupId":"OG001","value":"-2","spread":"5"},{"groupId":"OG002","value":"8","spread":"12"},{"groupId":"OG003","value":"8","spread":"8"},{"groupId":"OG004","value":"6","spread":"13"},{"groupId":"OG005","value":"1","spread":"8"}]}]},{"title":"Lipase: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"6"},{"groupId":"OG001","value":"0","spread":"4"},{"groupId":"OG002","value":"8","spread":"7"},{"groupId":"OG003","value":"1","spread":"2"},{"groupId":"OG004","value":"9","spread":"6"},{"groupId":"OG005","value":"0","spread":"3"}]}]},{"title":"ALT: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-9","spread":"32"},{"groupId":"OG001","value":"-4","spread":"18"},{"groupId":"OG002","value":"-2","spread":"6"},{"groupId":"OG003","value":"-25","spread":"23"},{"groupId":"OG004","value":"-6","spread":"25"},{"groupId":"OG005","value":"-10","spread":"21"}]}]},{"title":"AST: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-6","spread":"14"},{"groupId":"OG001","value":"0","spread":"10"},{"groupId":"OG002","value":"-2","spread":"5"},{"groupId":"OG003","value":"-18","spread":"24"},{"groupId":"OG004","value":"-4","spread":"11"},{"groupId":"OG005","value":"-6","spread":"17"}]}]},{"title":"ALP: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-10","spread":"12"},{"groupId":"OG001","value":"-7","spread":"25"},{"groupId":"OG002","value":"-21","spread":"36"},{"groupId":"OG003","value":"-47","spread":"42"},{"groupId":"OG004","value":"-14","spread":"24"},{"groupId":"OG005","value":"-19","spread":"35"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Creatine Kinase, Amylase, Lipase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) From Baseline at Week 52","description":"Change in creatine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units per liter (U/L)","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Creatinine kinase: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":"206"},{"groupId":"OG001","value":"-4","spread":"29"},{"groupId":"OG002","value":"25","spread":"42"},{"groupId":"OG003","value":"-8","spread":"25"},{"groupId":"OG004","value":"28","spread":"159"},{"groupId":"OG005","value":"-5","spread":"27"}]}]},{"title":"Amylase: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":"10"},{"groupId":"OG001","value":"2","spread":"12"},{"groupId":"OG002","value":"7","spread":"12"},{"groupId":"OG003","value":"8","spread":"5"},{"groupId":"OG004","value":"5","spread":"11"},{"groupId":"OG005","value":"4","spread":"11"}]}]},{"title":"Lipase: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":"9"},{"groupId":"OG001","value":"-1","spread":"3"},{"groupId":"OG002","value":"7","spread":"6"},{"groupId":"OG003","value":"3","spread":"5"},{"groupId":"OG004","value":"8","spread":"8"},{"groupId":"OG005","value":"0","spread":"4"}]}]},{"title":"ALT: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"12"},{"groupId":"OG001","value":"4","spread":"25"},{"groupId":"OG002","value":"0","spread":"16"},{"groupId":"OG003","value":"-24","spread":"28"},{"groupId":"OG004","value":"1","spread":"14"},{"groupId":"OG005","value":"-6","spread":"29"}]}]},{"title":"AST: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"7"},{"groupId":"OG001","value":"9","spread":"31"},{"groupId":"OG002","value":"1","spread":"7"},{"groupId":"OG003","value":"-21","spread":"32"},{"groupId":"OG004","value":"-1","spread":"7"},{"groupId":"OG005","value":"0","spread":"33"}]}]},{"title":"ALP: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-24","spread":"27"},{"groupId":"OG001","value":"-35","spread":"27"},{"groupId":"OG002","value":"-25","spread":"59"},{"groupId":"OG003","value":"-26","spread":"60"},{"groupId":"OG004","value":"-24","spread":"42"},{"groupId":"OG005","value":"-32","spread":"39"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 16","description":"Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"Urea: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"1.45"},{"groupId":"OG001","value":"-0.51","spread":"0.67"},{"groupId":"OG002","value":"0","spread":"0.99"},{"groupId":"OG003","value":"0.09","spread":"2.19"},{"groupId":"OG004","value":"0.02","spread":"1.26"},{"groupId":"OG005","value":"-0.31","spread":"1.33"}]}]},{"title":"Sodium: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"5"},{"groupId":"OG001","value":"2","spread":"3"},{"groupId":"OG002","value":"1","spread":"4"},{"groupId":"OG003","value":"0","spread":"1"},{"groupId":"OG004","value":"0","spread":"4"},{"groupId":"OG005","value":"1","spread":"3"}]}]},{"title":"Potassium: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.4"},{"groupId":"OG001","value":"-0.1","spread":"0.3"},{"groupId":"OG002","value":"-0.2","spread":"0.6"},{"groupId":"OG003","value":"-0.1","spread":"0.2"},{"groupId":"OG004","value":"0","spread":"0.5"},{"groupId":"OG005","value":"-0.1","spread":"0.2"}]}]},{"title":"Calcium: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.12"},{"groupId":"OG001","value":"0","spread":"0.10"},{"groupId":"OG002","value":"0.08","spread":"0.17"},{"groupId":"OG003","value":"0.02","spread":"0.10"},{"groupId":"OG004","value":"0.03","spread":"0.14"},{"groupId":"OG005","value":"0.01","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Urea, Sodium, Potassium, Calcium Total and Calcium Albumin-corrected From Baseline at Week 52","description":"Change in urea, sodium, potassium, calcium total and calcium albumin-corrected from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mmol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"Urea: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.38","spread":"1.56"},{"groupId":"OG001","value":"-0.34","spread":"0.54"},{"groupId":"OG002","value":"-0.21","spread":"1.00"},{"groupId":"OG003","value":"-0.04","spread":"1.08"},{"groupId":"OG004","value":"-0.31","spread":"1.34"},{"groupId":"OG005","value":"-0.24","spread":"0.74"}]}]},{"title":"Sodium: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1","spread":"5"},{"groupId":"OG001","value":"-2","spread":"5"},{"groupId":"OG002","value":"1","spread":"4"},{"groupId":"OG003","value":"2","spread":"2"},{"groupId":"OG004","value":"0","spread":"4"},{"groupId":"OG005","value":"-1","spread":"4"}]}]},{"title":"Potassium: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.6"},{"groupId":"OG001","value":"-0.1","spread":"0.2"},{"groupId":"OG002","value":"-0.2","spread":"0.7"},{"groupId":"OG003","value":"0","spread":"0.2"},{"groupId":"OG004","value":"-0.2","spread":"0.6"},{"groupId":"OG005","value":"-0.1","spread":"0.2"}]}]},{"title":"Calcium: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.14"},{"groupId":"OG001","value":"-0.11","spread":"0.12"},{"groupId":"OG002","value":"0.09","spread":"0.14"},{"groupId":"OG003","value":"0","spread":"0.02"},{"groupId":"OG004","value":"0.01","spread":"0.15"},{"groupId":"OG005","value":"-0.08","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Albumin From Baseline at Week 16","description":"Change in albumin from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"gram per deciliter (g/dL)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0.2"},{"groupId":"OG001","value":"0","spread":"0.1"},{"groupId":"OG002","value":"0","spread":"0.2"},{"groupId":"OG003","value":"0","spread":"0.1"},{"groupId":"OG004","value":"0","spread":"0.2"},{"groupId":"OG005","value":"0","spread":"0.1"}]}]}]},{"type":"SECONDARY","title":"Change in Biochemistry: Albumin From Baseline at Week 52","description":"Change in albumin from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"g/dL","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.7"},{"groupId":"OG001","value":"-0.1","spread":"0.3"},{"groupId":"OG002","value":"0","spread":"0.2"},{"groupId":"OG003","value":"0","spread":"0.1"},{"groupId":"OG004","value":"0","spread":"0.5"},{"groupId":"OG005","value":"-0.1","spread":"0.2"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 16","description":"Change in CEA serum from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"15"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.11"},{"groupId":"OG001","value":"-0.17","spread":"0.30"},{"groupId":"OG002","value":"0.17","spread":"0.55"},{"groupId":"OG003","value":"-0.04","spread":"0.10"},{"groupId":"OG004","value":"0.07","spread":"0.38"},{"groupId":"OG005","value":"-0.12","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Carcinoembryonic Antigen (CEA) From Baseline at Week 52","description":"Change in CEA serum from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.38"},{"groupId":"OG001","value":"-0.14","spread":"0.26"},{"groupId":"OG002","value":"-0.01","spread":"0.14"},{"groupId":"OG003","value":"0.17","spread":"0.24"},{"groupId":"OG004","value":"0.01","spread":"0.29"},{"groupId":"OG005","value":"-0.01","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Calcitonin From Baseline at Week 16","description":"Change in calcitonin from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per liter (ng/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0.3","spread":"1.1"},{"groupId":"OG003","value":"0","spread":"0"},{"groupId":"OG004","value":"0.1","spread":"0.7"},{"groupId":"OG005","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Calcitonin From Baseline at Week 52","description":"Change in calcitonin from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.6"},{"groupId":"OG001","value":"0","spread":"0"},{"groupId":"OG002","value":"0.5","spread":"1.2"},{"groupId":"OG003","value":"0","spread":"0"},{"groupId":"OG004","value":"0.3","spread":"0.9"},{"groupId":"OG005","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 16","description":"Change in TSH and prolactin from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Milli-international units/liter (mIU/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"TSH: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.34","spread":"0.68"},{"groupId":"OG001","value":"-0.01","spread":"0.72"},{"groupId":"OG002","value":"-0.09","spread":"1.13"},{"groupId":"OG003","value":"-0.59","spread":"0.67"},{"groupId":"OG004","value":"-0.23","spread":"0.89"},{"groupId":"OG005","value":"-0.23","spread":"0.74"}]}]},{"title":"Prolactin: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"27"},{"groupId":"OG001","value":"-6","spread":"33"},{"groupId":"OG002","value":"0","spread":"13"},{"groupId":"OG003","value":"-22","spread":"63"},{"groupId":"OG004","value":"4","spread":"22"},{"groupId":"OG005","value":"-12","spread":"45"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Thyroid Stimulating Hormone (TSH) and Prolactin From Baseline at Week 52","description":"Change in TSH and prolactin from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"mIU/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"TSH: Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"1.59"},{"groupId":"OG001","value":"-0.48","spread":"0.63"},{"groupId":"OG002","value":"-0.75","spread":"2.13"},{"groupId":"OG003","value":"-0.17","spread":"1.08"},{"groupId":"OG004","value":"-0.30","spread":"1.83"},{"groupId":"OG005","value":"-0.38","spread":"0.78"}]}]},{"title":"Prolactin: Change from week 0 to week 52","categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"38"},{"groupId":"OG001","value":"8","spread":"37"},{"groupId":"OG002","value":"-3","spread":"37"},{"groupId":"OG003","value":"29","spread":"33"},{"groupId":"OG004","value":"5","spread":"37"},{"groupId":"OG005","value":"15","spread":"36"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 16","description":"Change in free T4 and ACTH from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"picomole per liter (pmol/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"T4: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.4"},{"groupId":"OG001","value":"0.3","spread":"1.1"},{"groupId":"OG002","value":"0.7","spread":"2.3"},{"groupId":"OG003","value":"0.1","spread":"1.7"},{"groupId":"OG004","value":"-0.1","spread":"1.9"},{"groupId":"OG005","value":"0.2","spread":"1.3"}]}]},{"title":"ACTH: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"5.22"},{"groupId":"OG001","value":"-0.85","spread":"2.22"},{"groupId":"OG002","value":"-0.37","spread":"1.49"},{"groupId":"OG003","value":"-1.32","spread":"1.87"},{"groupId":"OG004","value":"0.42","spread":"4.10"},{"groupId":"OG005","value":"-1.02","spread":"2.04"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Free Thyroxine (Free T4) and Adrenocorticotropic Hormone (ACTH) From Baseline at Week 52","description":"Change in free T4 and ACTH from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pmol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"T4: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"1.7"},{"groupId":"OG001","value":"1.9","spread":"2.7"},{"groupId":"OG002","value":"-0.1","spread":"2.0"},{"groupId":"OG003","value":"0.8","spread":"2.3"},{"groupId":"OG004","value":"-0.3","spread":"1.8"},{"groupId":"OG005","value":"1.5","spread":"2.5"}]}]},{"title":"ACTH: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"2.02"},{"groupId":"OG001","value":"1.29","spread":"3.50"},{"groupId":"OG002","value":"0.98","spread":"5.64"},{"groupId":"OG003","value":"0.20","spread":"2.41"},{"groupId":"OG004","value":"0.42","spread":"3.99"},{"groupId":"OG005","value":"0.89","spread":"3.07"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 16","description":"Change in IGF-1 and cortisol from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"classes":[{"title":"IGF-1: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-56.89","spread":"126.46"},{"groupId":"OG001","value":"-28.23","spread":"95.79"},{"groupId":"OG002","value":"2.41","spread":"84.98"},{"groupId":"OG003","value":"-14.23","spread":"75.01"},{"groupId":"OG004","value":"-30.31","spread":"112.09"},{"groupId":"OG005","value":"-23.86","spread":"87.54"}]}]},{"title":"Cortisol: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-22.94","spread":"41.36"},{"groupId":"OG001","value":"6.75","spread":"38.72"},{"groupId":"OG002","value":"-8.09","spread":"22.98"},{"groupId":"OG003","value":"-23.08","spread":"59.02"},{"groupId":"OG004","value":"-16.71","spread":"35.16"},{"groupId":"OG005","value":"-4.85","spread":"48.33"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Insulin-like Growth Factor-1 (IGF-1) and Cortisol From Baseline at Week 52","description":"Change in IGF-1 and cortisol from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng/mL","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"14"}]}],"classes":[{"title":"IGF-1: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-25.90","spread":"195.61"},{"groupId":"OG001","value":"-103.45","spread":"136.61"},{"groupId":"OG002","value":"-1.47","spread":"112.93"},{"groupId":"OG003","value":"10.40","spread":"56.69"},{"groupId":"OG004","value":"-15.04","spread":"161.72"},{"groupId":"OG005","value":"-59.66","spread":"123.62"}]}]},{"title":"Cortisol: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":"50.63"},{"groupId":"OG001","value":"7.54","spread":"33.71"},{"groupId":"OG002","value":"-14.15","spread":"43.84"},{"groupId":"OG003","value":"21.67","spread":"46.62"},{"groupId":"OG004","value":"-4.01","spread":"47.82"},{"groupId":"OG005","value":"12.59","spread":"37.65"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 16","description":"Change in DHEAS from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"16"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"1.74"},{"groupId":"OG001","value":"0.21","spread":"0.95"},{"groupId":"OG002","value":"0.25","spread":"1.10"},{"groupId":"OG003","value":"1.00","spread":"1.42"},{"groupId":"OG004","value":"0.20","spread":"1.48"},{"groupId":"OG005","value":"0.46","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Dehydroepiandrosterone Sulfate (DHEAS) From Baseline at Week 52","description":"Change in DHEAS from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"umol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.77","spread":"1.18"},{"groupId":"OG001","value":"0.76","spread":"0.97"},{"groupId":"OG002","value":"0.25","spread":"0.66"},{"groupId":"OG003","value":"0.74","spread":"1.26"},{"groupId":"OG004","value":"0.55","spread":"1.01"},{"groupId":"OG005","value":"0.76","spread":"1.01"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 16","description":"Change in LH and FSH from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/L","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"LH: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"30"},{"groupId":"OG005","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"1.28"},{"groupId":"OG001","value":"0.06","spread":"0.74"},{"groupId":"OG002","value":"-0.07","spread":"0.25"},{"groupId":"OG003","value":"0.22","spread":"0.42"},{"groupId":"OG004","value":"-0.05","spread":"0.97"},{"groupId":"OG005","value":"0.12","spread":"0.63"}]}]},{"title":"FSH: Change from week 0 to week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.5"},{"groupId":"OG001","value":"0.2","spread":"1.0"},{"groupId":"OG002","value":"-0.1","spread":"1.3"},{"groupId":"OG003","value":"1.0","spread":"1.1"},{"groupId":"OG004","value":"-0.2","spread":"2.1"},{"groupId":"OG005","value":"0.5","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Luteinising Hormone (LH), Follicle Stimulating Hormone (FSH) From Baseline at Week 52","description":"Change in LH and FSH from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"IU/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"classes":[{"title":"LH: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.16","spread":"2.33"},{"groupId":"OG001","value":"0.06","spread":"0.79"},{"groupId":"OG002","value":"0.37","spread":"0.96"},{"groupId":"OG003","value":"0.30","spread":"0.51"},{"groupId":"OG004","value":"0.24","spread":"1.87"},{"groupId":"OG005","value":"0.14","spread":"0.70"}]}]},{"title":"FSH: Change from week 0 to week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.9"},{"groupId":"OG001","value":"0.4","spread":"1.6"},{"groupId":"OG002","value":"0.4","spread":"1.8"},{"groupId":"OG003","value":"0.7","spread":"1.6"},{"groupId":"OG004","value":"0.8","spread":"3.1"},{"groupId":"OG005","value":"0.6","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Estradiol (Females) From Baseline at Week 16","description":"Change in estradiol (only for females) from baseline to week 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of female participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"picograms per milliliter (pg/mL)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"15.8"},{"groupId":"OG001","value":"9.2","spread":"11.9"},{"groupId":"OG002","value":"1.6","spread":"3.8"},{"groupId":"OG003","value":"0","spread":"0"},{"groupId":"OG004","value":"1.2","spread":"12.2"},{"groupId":"OG005","value":"6.1","spread":"10.4"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Estradiol (Females) From Baseline at Week 52","description":"Change in estradiol (only for females) from baseline to week 52 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of female participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"pg/mL","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","spread":"32.6"},{"groupId":"OG001","value":"13.7","spread":"21.6"},{"groupId":"OG002","value":"1.6","spread":"4.5"},{"groupId":"OG003","value":"0","spread":"NA","comment":"As there was only one participant evaluated for the Part B: Placebo arm; Mean and SD could not be calculated."},{"groupId":"OG004","value":"4.1","spread":"21.8"},{"groupId":"OG005","value":"11.0","spread":"19.7"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Testosterone (Males) From Baseline at Week 16","description":"Change in testosterone (only for males) from baseline to week 16 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of male participants who contributed to the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanomoles per liter (nmol/L)","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.55","spread":"2.01"},{"groupId":"OG001","value":"0.61","spread":"1.66"}]}]}]},{"type":"SECONDARY","title":"Change in Hormone Level: Testosterone (Males) From Baseline at Week 52","description":"Change in testosterone (only for males) from baseline to week 52 is presented. The testosterone analysis for Part B could not be performed due to an unforeseen change in the assay used by the central laboratory to measure testosterone during the trial. This change in methodology prevented a direct comparison of values measured at different time points during the trial.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of male participants who contributed to the analysis.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nmol/L","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":"1.40"},{"groupId":"OG001","value":"-0.34","spread":"1.51"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Pubertal Status From Baseline at Week 16","description":"This outcome measure presents \"pubertal status results\" which is based on Tanner staging recorded at baseline (week 0), week 16. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents \"early pubertal development\" and stage 5 represents \"pubertal development equivalent to that of an adult\".","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"12"}]}],"classes":[{"title":"Week 0: Breast development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 16: Breast development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 0: Pubic hair development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 16: Pubic hair development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 0: Pubic hair development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 16: Pubic hair development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 0: Penis development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 16: Penis development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Pubertal Status From Baseline at Week 52","description":"This outcome measure presents \"pubertal status results\" which is based on Tanner staging recorded at baseline (week 0) and week 52. Tanner Stages is a scale that defines physical measurements of development based on external primary and secondary sex characteristics. It was used in this study to assess pubertal development with values ranging from Stage 1 (pre-pubertal characteristics) to Stage 5 (adult or mature characteristics). Results are presented for the following categories: 1) For female: breast development and pubic hair development, 2) For male: penis development and pubic hair development. Each category shows number of participants in stages 1 to 5, where stage 1 represents \"early pubertal development\" and stage 5 represents \"pubertal development equivalent to that of an adult\".","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"12"}]}],"classes":[{"title":"Week 0: Breast development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 52: Breast development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"6"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 0: Pubic hair development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"7"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 52: Pubic hair development (for female)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"6"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Week 0: Pubic hair development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"5"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 52: Pubic hair development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"9"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"0"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]},{"title":"Week 0: Penis development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"Week 52: Penis development (for male)","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"9"}]}],"categories":[{"title":"Stage 1","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Stage 2","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 3","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]},{"title":"Stage 4","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]},{"title":"Stage 5","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Physical Examination From Baseline at Week 16","description":"This outcome measure presents number of participants with physical examination findings, \"normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)\" at baseline (week 0), week 16. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"General Appearance: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]}]},{"title":"General Appearance: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"2"}]}]},{"title":"Head, ears, eyes, nose, throat, neck: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Head, ears, eyes, nose, throat, neck: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Respiratory system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Respiratory system: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Cardiovascular system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Cardiovascular system: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"33"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"GI system including mouth: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"GI system including mouth: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Musculoskeletal system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Musculoskeletal system: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]}]},{"title":"CNS and PNS: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}]},{"title":"CNS and PNS: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"18"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Skin: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Skin: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"14"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"3"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"}]}]},{"title":"Thyroid gland: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Thyroid gland: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymph node palpation: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymph node palpation: Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Physical Examination From Baseline at Week 52","description":"This outcome measure presents number of participants with physical examination findings, \"normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)\" at baseline (week 0) and week 52. These findings were categorised by the investigator. Results include examination of: general appearance; head, ears, eyes, nose, throat, neck; respiratory system; cardiovascular system (CVS); gastrointestinal (GI) system including mouth; musculoskeletal system; central nervous system (CNS) and peripheral nervous system (PNS); skin; thyroid gland and lymph node palpation.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"classes":[{"title":"General Appearance: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]}]},{"title":"General Appearance: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Head, ears, eyes, nose, throat, neck: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Head, ears, eyes, nose, throat, neck: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Respiratory system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Cardiovascular system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Cardiovascular system: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"GI system including mouth: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"GI system including mouth: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Musculoskeletal system: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"}]}]},{"title":"Musculoskeletal system: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"15"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"CNS and PNS: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"}]}]},{"title":"CNS and PNS: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"14"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"}]}]},{"title":"Skin: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"13"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"}]}]},{"title":"Skin: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"12"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"}]}]},{"title":"Thyroid gland: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Thyroid gland: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymph node palpation: Week 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"37"},{"groupId":"OG005","value":"19"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"19"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Lymph node palpation: Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]}],"categories":[{"title":"Normal","measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"16"}]},{"title":"Abnormal, NCS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]},{"title":"Abnormal, CS","measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Height Velocity at Week 16","description":"Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Weeks 16 is presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeters/year (cm/yr)","timeFrame":"Week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"34"},{"groupId":"OG005","value":"19"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.113","spread":"3.084"},{"groupId":"OG001","value":"2.718","spread":"4.281"},{"groupId":"OG002","value":"4.190","spread":"2.604"},{"groupId":"OG003","value":"6.898","spread":"2.886"},{"groupId":"OG004","value":"3.090","spread":"3.014"},{"groupId":"OG005","value":"4.258","spread":"4.274"}]}]}]},{"type":"SECONDARY","title":"Height Velocity at Week 52","description":"Height velocity was the change in height per year. The height velocity was calculated as the difference between current height and baseline divided by by time duration in days between those measurement time points and multiplied by 365 days. Height velocity calculated at Week 52 are presented.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Combined data of Part A and B for liraglutide and placebo was planned to be reported.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Centimeters/year (cm/yr)","timeFrame":"week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG002","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."},{"id":"OG004","title":"Part A+B: Liraglutide","description":"Participants received once daily subcutaneous (under the skin) injection of liraglutide for 52 weeks (open label for 16 weeks and double-blinded for 36 weeks ) in a dose escalating manner. For both part A and part B (for children with body weight ≥ 45 kilograms (kg)): dosing was initiated with liraglutide 0.6 milligrams (mg) daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For Part B children with body weight \\< 45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52)."},{"id":"OG005","title":"Part A+B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks (open label)."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"31"},{"groupId":"OG005","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.564","spread":"1.285"},{"groupId":"OG001","value":"1.839","spread":"1.658"},{"groupId":"OG002","value":"4.752","spread":"2.250"},{"groupId":"OG003","value":"5.620","spread":"1.690"},{"groupId":"OG004","value":"3.004","spread":"2.383"},{"groupId":"OG005","value":"3.173","spread":"2.466"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 16","description":"C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \\[C-CASA\\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is \"yes\" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is \"yes\" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with \"suicidal ideation or suicidal behaviour on C-SSRS\" assessed at baseline (week 0), week 16. The questionnaire was not used in Part B due to the young age of the participants in Part B.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. This outcome measure was planned to be analyzed for Part A only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Week 0: Suicidal ideation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Week 0: Suicidal behaviour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Week 16: Suicidal ideation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Week 16: Suicidal behaviour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Change in Columbia Suicidality Severity Rating Scale (C-SSRS) at Week 52","description":"C-SSRS (mapped to Columbia Classification Algorithm of Suicide Assessment \\[C-CASA\\]) is an interview-based rating scale to systematically assess suicidality, suicidal behaviour, suicidal ideation. Suicidality: emergence of any suicidal ideation or suicidal behaviour. Suicidal behaviour: when response is \"yes\" for any of the questions- actual attempt to suicide, engaged in non-suicidal self-injurious behaviour, interrupted attempt, aborted attempt, preparatory acts. Suicidal ideation: when response is \"yes\" for any of the questions- wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent to suicide. This outcome measure presents number of participants with \"suicidal ideation or suicidal behaviour on C-SSRS\" assessed at baseline (week 0), week 52. The questionnaire was not used in Part B due to the young age of the participants in Part B.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. Number Analyzed = number of participants with available data. This outcome measure was planned to be analyzed for Part A only.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"classes":[{"title":"Week 0: Suicidal ideation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Week 0: Suicidal behaviour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"12"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Week 52: Suicidal ideation","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Week 52: Suicidal behaviour","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 16","description":"Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 16. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. This outcome measure was planned to be analyzed for Part A only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 16","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"4"},{"groupId":"OG001","value":"1","spread":"5"}]}]}]},{"type":"SECONDARY","title":"Part A: Change in Patient Reported Health Questionnaire-9 (PHQ-9) From Baseline at Week 52","description":"Change in Patient Health Questionnaire 9 (PHQ-9) was evaluated from baseline (week 0) to weeks 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. The PHQ-9 total score ranges from 0-27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15-19 represent moderately severe depression and total scores of 20-27 represent severe depression. The questionnaire was not used in Part B due to the young age of the participants in Part B.","populationDescription":"SAS which included all participants exposed to at least one dose of trial product. Overall Number of Participants Analyzed = number of participants who contributed to the analysis. This outcome measure was planned to be analyzed for Part A only.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on a scale","timeFrame":"Week 0, week 52","groups":[{"id":"OG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52)."},{"id":"OG001","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":"3"},{"groupId":"OG001","value":"0","spread":"3"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From week 0 to week 54 Results are based on SAS which included all participants exposed to at least one dose of trial product. All AEs reported here are TEAEs. TEAE is as an event that had onset date during on-treatment period.","description":"On-treatment period: included AEs with onset date on or after first day of trial product administration; any of following dates, whichever came first: a) 14 days after last day on trial product, or b) Follow-up visit (week54) for participants with trial product discontinuation or c) Last study visit (participants withdrawn without follow-up visit (week 54)).","eventGroups":[{"id":"EG000","title":"Part A: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. Dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a maximum tolerated dose (MTD) (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52).","deathsNumAffected":0,"deathsNumAtRisk":20,"seriousNumAffected":1,"seriousNumAtRisk":20,"otherNumAffected":16,"otherNumAtRisk":20},{"id":"EG001","title":"Part B: Liraglutide","description":"Participants received once daily subcutaneous injection of liraglutide for 52 weeks. For children with body weight ≥ 45 kg; dosing was initiated with liraglutide 0.6 mg daily for one week and increased in weekly dosage steps of 0.6 mg until a MTD (as judged by the Investigator) or a dose of 3.0 mg liraglutide was reached, i.e., 0.6 mg (week 1), 1.2 mg (week 2), 1.8 mg (week 3), 2.4 mg (week 4) and 3.0 mg (week 5 to week 52). For children with body weight \\<45 kg: dosing was initiated with liraglutide 0.3 mg daily for one week and increased to 0.6 mg after the first week. Thereafter, the dose was increased in weekly steps of 0.6 mg until an MTD (as judged by the Investigator) or a dose of 2.4 mg liraglutide was reached. i.e., 0.3 mg (week 1), 0.6 mg (week 2), 1.2 mg (week 3), 1.8 mg (week 4), 2.4 mg (week 5 to week 52).","deathsNumAffected":0,"deathsNumAtRisk":17,"seriousNumAffected":2,"seriousNumAtRisk":17,"otherNumAffected":17,"otherNumAtRisk":17},{"id":"EG002","title":"Part A: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks.","deathsNumAffected":0,"deathsNumAtRisk":12,"seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":10,"otherNumAtRisk":12},{"id":"EG003","title":"Part B: Placebo","description":"Participants received once daily subcutaneous injection of placebo matched to liraglutide for 16 weeks.","deathsNumAffected":0,"deathsNumAtRisk":7,"seriousNumAffected":1,"seriousNumAtRisk":7,"otherNumAffected":4,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Arthrodesis","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Spinal operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]}],"otherEvents":[{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":20},{"groupId":"EG001","numEvents":12,"numAffected":3,"numAtRisk":17},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal rigidity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acarodermatitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Adenoidal hypertrophy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Amenorrhoea","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anaemia postoperative","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthropod bite","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Behaviour disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood calcitonin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood insulin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dental caries","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":10,"numAtRisk":20},{"groupId":"EG001","numEvents":62,"numAffected":7,"numAtRisk":17},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ear infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ear tube insertion","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Forearm fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrointestinal viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Glycosylated haemoglobin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hallucination, auditory","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatocellular injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated thyroiditis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Impetigo","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":7}]},{"term":"Injection site bruising","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Injection site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Injection site nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insulin resistance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insulin-like growth factor decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Knee deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Low density lipoprotein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":20},{"groupId":"EG001","numEvents":5,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Overflow diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain prophylaxis","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Precocious puberty","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Respiratory tract infection viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin abrasion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin mass","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sleep apnoea syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Soft tissue injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Thyroxine free decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tic","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tinea versicolour","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tooth extraction","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vitamin D deficiency","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":20},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":20},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":17},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":12},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property."},"pointOfContact":{"title":"Clinical Transparency and Medical Writing Office (1452)","organization":"Novo Nordisk A/S","email":"clinicaltrials@novonordisk.com","phone":"(+1) 866-867-7178"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2021-03-25","uploadDate":"2021-10-27T10:26","filename":"Prot_000.pdf","size":2877319},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-12-14","uploadDate":"2021-10-27T10:26","filename":"SAP_001.pdf","size":640200}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}